Schizophrenia

Strategic Alliance Extension Announced in Genetic Study

Published in Gene Therapy Weekly, July 7th, 1997

Algene Biotechnologies Corp., Montreal, Quebec, Canada, announced that it and Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson, have agreed to further extend their scientific collaboration for the identification of genes that cause schizophrenia.

Under the terms of this extension, Algene undertakes a series of gene mapping experiments to identify chromosomal regions that could harbor causal genes in schizophrenia.

In the framework of the collaboration originally established in 1995 with Janssen, Algene applied its technology platform to select cases of schizophrenia and to initiate causal gene mapping experimentation. A first...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry